{"id":54813,"date":"2020-12-08T13:03:28","date_gmt":"2020-12-08T12:03:28","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=54813"},"modified":"2022-07-16T08:32:03","modified_gmt":"2022-07-16T06:32:03","slug":"simbec-orion-streamlines-trial-execution-with-veeva-clinical-applications","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/simbec-orion-streamlines-trial-execution-with-veeva-clinical-applications\/","title":{"rendered":"Simbec-Orion Streamlines Trial Execution with Veeva Clinical Applications"},"content":{"rendered":"

Vault CTMS and Vault eTMF provide complete visibility into trials,
\nenabling CRO to deliver value-added services to sponsors<\/em><\/p>\n

BARCELONA, Spain \u2014 8 Dec., 2020 \u2014<\/strong>Veeva Systems<\/a> (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS<\/a> and Veeva Vault eTMF<\/a> to digitize end-to-end clinical trial data, workflows, and documents. Veeva clinical applications will give Simbec-Orion real-time insights into studies across phases to accelerate trial execution. <\/p>\n

\u201cVeeva provides the digital foundation to run complex clinical trials and keep studies on track,\u201d said Jim Kendall, chief information officer at Simbec-Orion.<\/p>\n

Veeva Vault unifies clinical processes on a single platform to streamline information sharing with sponsors and ensure compliance with GCP requirements. For example, monitoring reports created in Vault CTMS can be automatically filed in Vault eTMF to improve efficiency and speed. <\/p>\n

\u201cOur teams will have the transparency to run effective trials and make agile decisions,\u201d said Narinder Virk, director of project management at Simbec-Orion. \u201cThis can speed-up execution and improve study delivery while maintaining high-quality data for sponsors.\u201d <\/p>\n

\u201cAdaptive CROs like Simbec-Orion are modernizing clinical processes to deliver differentiated services to sponsors,\u201d said Rik Van Mol, vice president of strategy for Veeva Development Cloud. \u201cVeeva Vault enables a more connected way of working with stakeholders for increased productivity and efficiency in trials.\u201d<\/p>\n

Vault CTMS and Vault eTMF are part of Veeva Vault Clinical Operations Suite<\/a>, enabling sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, and study start-up for better collaboration and increased efficiency throughout the study lifecycle. <\/p>\n

Veeva recently announced that a growing number of companies are simplifying end-to-end study management with Veeva Vault CTMS for greater visibility and speed in trials. Read the press release<\/a> to learn more. <\/p>\n

Additional Information<\/strong>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n

About Simbec-Orion<\/strong>
\nSimbec-Orion is a responsive and agile full-service CRO with specialist expertise in clinical pharmacology, oncology, and rare diseases. Perfectly structured, we provide full-service clinical development solutions for small and mid-size drug developers \u2013 headed up by a centralized leadership team. With a focus on tailormade and scalable solutions, we\u2019ll adapt our delivery style, communications, and operations to suit the demands of your project, helping you achieve your clinical and commercial objectives. Because our goal is the same as yours; to improve patients\u2019 lives. For more information, visit simbecorion.com<\/a>. <\/p>\n

About Veeva Systems<\/strong>
\nVeeva Systems Inc. is a leader in cloud solutions\u2014including data, software, and services\u2014for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n

###<\/p>\n

Contact:<\/strong><\/p>\n

Veeva Systems
\npr@veeva.com<\/a><\/p>\n

Deivis Mercado
\nVeeva Systems
\n925-226-8821
\ndeivis.mercado@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CRO adopts Vault CTMS and Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents.<\/p>\n","protected":false},"featured_media":54815,"parent":0,"template":"","class_list":["post-54813","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-operations","resource-product-20-ctms","resource-type-news-press-release"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t